A Search for the Write Stuff

Peter Ward, a marine biologist at the University of Washington in Seattle, is fascinated by the chambered nautilus, the lone survivor of an entire subclass of molluscs that emerged some 500 million years ago. In the course of thinking about how to open this world to the public—whom he calls "the real supporters of science"—Ward received a flyer describing a new publishing venture by the New York Academy of Sciences. The result is In Search of Nautilus, one of the first in a series d

Written byAmy Mcdonald
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The result is In Search of Nautilus, one of the first in a series designed to encourage scientists to write non-technical books with mass-market appeal. Begun in 1986, the series—entitled The Scientific Prospect—is meant to serve scientists eager to become authors but ignorant of how to go about it.

"The idea of showing the public how science is done intrigued me," said Ward. "As a university professor, I think it is one of the things we do least well. I tried to write a book I would've liked to have read when I was just starting out in science."

Proposals for The Scientific Prospect are reviewed by an editorial board of 10 well-known scientists. Accepted authors sign with the project and John Brockman Associates, the literary agent. Simon and Shuster is the publisher for the series.

A typical advance is $20,000, as much as 50 percent more than those for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies